Developing inflammasome inhibitors for the treatment of age-related and orphan inflammatory diseases

Inflazome is developing first in class, orally available drugs to address clinical unmet needs by targeting activation of the inflammasome. The inflammasome is associated with harmful inflammation in a broad range of serious medical conditions including Alzheimer’s, Parkinson’s, inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases. The company has proprietary new chemical entities that inhibit inflammasome-driven release of pro-inflammatory cytokines that exacerbate inflammation. In addition, they block innate immune cell pyroptosis (uncontrolled cell death), a process that leads to chronic inflammation.

  • CEO Matt Cooper
  • Industry Biotech